8
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before September 30, 2024

      About Blood Purification: 2.2 Impact Factor I 5.8 CiteScore I 0.782 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Efficient Removal of Albumin-Bound Furancarboxylic Acid, an Inhibitor of Erythropoiesis, by Continuous Ambulatory Peritoneal Dialysis

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid, which cannot be removed by conventional hemodialysis due to its strong albumin binding, was found to be efficiently removed by continuous ambulatory peritoneal dialysis (CAPD), resulting in a lower serum level in uremic patients on CAPD than in those on hemodialysis. 3-Carboxy-4-methyl-5-propyl-2-furanpropionic acid was demonstrated in vitro to inhibit erythroid colony formation. The anemia in patients on CAPD was significantly less severe than in those on hemodialysis. These results suggest that the efficient removal by CAPD of 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid, an inhibitor of erythropoiesis, is related to an improvement of anemia in patients on CAPD.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1990
          1990
          10 December 2008
          : 56
          : 3
          : 241-245
          Affiliations
          aDepartment of Internal Medicine, Nagoya University Branch Hospital, Nagoya; bKureha Chemical Industry, Tokyo, Japan
          Article
          186147 Nephron 1990;56:241–245
          10.1159/000186147
          2077405
          b3310c7c-d9fc-4073-811a-babc24018315
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 12 January 1990
          Page count
          Pages: 5
          Categories
          Original Paper

          Cardiovascular Medicine,Nephrology
          Uremia,Anemia,Continuous ambulatory peritoneal dialysis,Furancarboxylic acid,Albumin binding,Inhibitor of erythropoiesis

          Comments

          Comment on this article